The increase in IL-35+IL-10+ B cells was higher following IN compared to IP abatacept treatment (19.5%, P<0.0001 and 11.2%, P = 0.002 percentage of IL-35+IL-10+ cells in IN-treated and IP-treated lung tissues, respectively; as well as 11.1%, P<0.0001 and 4.9%, P = 0.004, percentage of IL-35+IL-10+ cells in IN-treated and IP-treated PBMCs, respectively) (Fig 2B and 2E). This evidence concerns the gene IL10 and incontinentia pigmenti.